Aligos Therapeutics Inc.

NASDAQ: ALGS · Real-Time Price · USD
7.70
0.12 (1.52%)
At close: Aug 15, 2025, 1:09 PM

Aligos Therapeutics Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
37M 135.7M 81.35M 186.82M
Short-Term Investments
19.94M n/a 44.48M 3.92M
Long-Term Investments
n/a n/a n/a 15.11M
Other Long-Term Assets
627K 625K -2.53M 866K
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
5.2M 5.38M 7.72M 13.69M
Total Current Assets
62.14M 141.08M 133.54M 204.42M
Property-Plant & Equipment
7.33M 9.82M 12.51M 14.97M
Goodwill & Intangibles
n/a n/a n/a -3.77M
Total Long-Term Assets
7.95M 10.44M 13.15M 30.95M
Total Assets
70.09M 151.53M 146.69M 235.37M
Account Payables
2.57M 2.52M 4.74M 3.02M
Deferred Revenue
151K 1.22M 9.21M 7.64M
Short-Term Debt
3.46M 3.24M 3.14M 2.91M
Other Current Liabilities
12.99M 14.41M 11.42M 21.25M
Total Current Liabilities
21.74M 23.91M 33.13M 38.96M
Long-Term Debt
4.92M 7.9M n/a n/a
Other Long-Term Liabilities
77.33M 27.64M n/a 133K
Total Long-Term Liabilities
77.33M 35.54M 9.66M 11.68M
Total Liabilities
99.07M 59.45M 42.79M 50.64M
Total Debt
8.38M 11.14M 12.57M 14.46M
Common Stock
8K 7K 4K 4K
Retained Earnings
-618.01M -486.8M -399.12M -303.07M
Comprehensive Income
451K 545K 401K 452K
Shareholders Equity
-28.97M 92.08M 103.9M 184.73M
Total Investments
19.94M -70K 44.48M 19.03M